Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial

Figure 3

Schematic view of the application sequences of the IMPs. (A) Patients in group 1 of phase I or II will receive the IMPs in the sequence depicted here. (B) Group 2 of phase II, which consists of patient that receive neoadjuvant therapy for resectable tumors will receive the IMPs in the sequence portrayed here.

Back to article page
\